Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0018681 (headache)
 56,091 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The mood and performance effects of caffeine deprivation (either 90 min, overnight, or at least 7 days) and ingestion (70 and 250 mg) were compared in young adults who were normally either moderate consumers (n = 49) or nonconsumers of caffeine (n = 18). Overnight caffeine deprivation produced dysphoric symptoms characteristic of caffeine withdrawal that were reduced, but still present, after longer-term abstinence. Acute caffeine intake affected the withdrawn consumers, nonwithdrawn consumers, and nonconsumers similarly. It increased jitteriness and decrease tiredness and headache. Furthermore, hand steadiness decreased as caffeine dose increased, whereas 70 mg, but not 250 mg, of caffeine was found to enhance performance on a simple reaction time task. These findings support the view that the negative effects experienced after overnight and longer-term caffeine deprivation play a significant role in influencing consumption of caffeine-containing drinks. Therefore, it would appear that to avoid the dysphoric symptoms resulting from both under- and overconsumption, regular caffeine consumers would have to regulate their caffeine intake fairly precisely.
 ...
PMID:Mood and performance effects of caffeine in relation to acute and chronic caffeine deprivation. 857 96

By the example of two case reports, typical signs of caffeine withdrawal like headache, increased irritability, decreased performance and disturbed concentration are described. These symptoms occurred two times within one week in two healthy nonsmoking individuals volunteering in a scientific study including periods of 24 hours with standardized caffeine-free-diet. The two volunteers were used to a regular coffee consumption of eight cups per day (about 600 mg/day). Since caffeine obviously represents the most common psycho-stimulant worldwide and since even moderate coffee consumption may lead to dependence, withdrawal symptoms induced by sudden reduction of consumption or withdrawal of caffeine may occur more often than usually assumed.
 ...
PMID:[Episodic headache, diminished performance and depressive mood]. 869 38

Because no contraceptive agent is perfect, patients must weigh the benefits and risks of the contraceptive method they decide to initiate and continue. Individual decision making and provider-client communication interact in complex ways to determine contraceptive behavior. Use of the contraceptive injectable depot medroxyprogesterone acetate (DMPA) should be preceded by counseling which individualizes its risks and benefits, answers all questions (asked and unasked), and develops a longterm plan to minimize side effects. Counseling should cover the contraceptive and noncontraceptive benefits of DMPA; specific side effects such as bleeding changes, weight changes, and fertility changes; the mechanisms of action; and ways to avoid acquiring sexually transmitted diseases. When evaluating and managing side effects, a differential diagnosis independent of DMPA must be considered first (especially for postcoital bleeding and headache). A pregnancy test should be offered in the first month of amenorrhea, after which no treatment is necessary. Ovulation resumption after use may be spontaneous or may be induced with menotropin therapy. Spotting and breakthrough bleeding may be handled by counseling or by a short course of high-dosage ibuprofen or of low-dose estrogen supplementation. Counseling may help women manage weight gain through caloric reduction and an increase in exercise. Acne which occurs soon after adoption of the method may be managed pharmacologically. Increased intake of dietary fiber and fluids may ameliorate the symptoms of abdominal bloating, and temporary nausea can be treated with antacids. Recent research has shown that depression does not increase with DMPA use, although the contraceptive is sometimes implicated in mood changes. Breast tenderness decreases with prolonged DMPA usage and can be managed with proper support garments and a reduction in other causative agents such as caffeine. Women who experience an increase in varicose veins should wear support hose and elevate their legs when possible. Women with symptoms of hypoestrogenic side effects should undergo a serum estradiol level test and appropriate replacement therapy. DMPA can be used immediately postpartum even in breast-feeding women. Women with amenorrhea should be tested for pregnancy before initiating DMPA or reinitiating use at an interval longer than 11-13 weeks. No adverse side effects have been found if pregnancy does occur.
 ...
PMID:Counseling issues and management of side effects for women using depot medroxyprogesterone acetate contraception. 872 1

Extremes of intracranial pressure commonly cause headache. Benign intracranial hypertension is a rare syndrome of increased intracranial pressure manifesting as headache, intracranial noises, transient visual obscuration, and palsy of the sixth cranial nerve. Endocrine disorders such as obesity and hypoparathyroidism, hypervitaminosis A, tetracycline use and thyroid replacement are probable causes of benign intracranial hypertension. In the majority of cases, however, it is idiopathic. Benign intracranial hypertension is though to be caused by cerebral edema, high cerebrospinal fluid outflow resistance and high cerebral venous pressure, or a combination of the three. The management of benign intracranial hypertension includes, symptomatic headache relief, removal of offending risk factor(s), and medical or surgical reduction of intracranial pressure. Spontaneous intracranial hypotension is more rare than benign intracranial hypertension. Postural headache (worse in the upright position) is the hallmark of spontaneous intracranial hypotension. Typically, the cerebrospinal fluid pressure is less than 60 mm H2O. Diminished cerebrospinal fluid production, hyperabsorption, and leak are postulated mechanisms of spontaneous intracranial hypotension. Empirical treatment includes bed rest, administration of caffeine, corticosteroids or mineralocorticoids, epidural blood patch, and epidural saline infusion.
 ...
PMID:Headache caused by raised intracranial pressure and intracranial hypotension. 883 14

Intracranial hypotension (IH) is present when cerebrospinal fluid (CSF) pressure is 60mm H2O or lower and there has been no previous dural puncture. IH is more common in women than in men (3:1). Orthostatic headache is the cardinal symptom. Visual, auditory, and other symptoms occur. Postulated mechanisms include sagging of the brain, dilation of intracranial veins, and activation of adenosine receptors. Examination may disclose visual field defects. The condition may be primary (probably related to an occult dural leak) or secondary to many causes that include lumbar puncture, trauma, pneumonectomy, diabetic coma, and uremia. Patients with postural headache should undergo neuroimaging prior to lumbar puncture. Radionuclide cisternography is the most sensitive means of demonstrating a CSF fistula. Severe, intractable headache associated with IH may respond to intravenous of oral caffeine. An epidural blood patch and epidural infusion of normal saline are treatment measures for symptoms of IH that follow lumbar puncture.
 ...
PMID:Intracranial hypotension. 887 51

Ergotamine tartrate (ET) and dihydroergotamine (DHE) are effective therapies for migraine and cluster headache. Optimal management with these agents must take several factors into account, including headache type and severity, associated symptoms, side effect potential, choice of dosage forms, and appropriate dosing. Oral ET is most appropriate for slowly evolving migraine without early onset nausea and/or vomiting, or for treatment of cluster headaches. Delivery of ET via rectal suppository (available only in combination with caffeine) is the most effective form, especially for patients with severe, rapid onset migraine accompanied by nausea and/or vomiting. Dihydroergotamine offers numerous benefits compared to ET, including a lower incidence of nausea and vomiting and headache recurrence, and a lack of rebound headache. Dihydroergotamine can be administered at any time during a migraine attack, including the aura. Intravenous administration provides rapid peak plasma levels and is the most effective form when a rapid effect is desired or for patients with intractable severe headache (status migrainosus, transformed migraine, rebound headache) and cluster headache. Intramuscular administration is effective for moderate to severe migraine with or without nausea and vomiting in the clinic. Intranasal delivery of DHE has shown significant promise for effective and convenient therapy in acute migraine and may be especially useful in the presence of nausea and/or vomiting. When used appropriately, DHE and ET provide clinicians with highly effective therapeutic options in a range of useful dosage forms for patients with migraine or cluster headaches.
Headache 1997
PMID:Dosing and administration of ergotamine tartrate and dihydroergotamine. 900 71

A 45-year-old female migraineur with a long-standing history of drug-induced headache is described. She had been abusing caffeine (250 mg/day) and aspirin (5 gr/day). On the third day after discontinuation a withdrawal syndrome characterized by headache and a generalized tonic-clonic seizure occurred. The temporal association makes it likely that the convulsion episode in an integral component of the withdrawal syndrome in this patient. This extra feature of the withdrawal syndrome has never been described after caffeine and/or aspirin interruption. Possible pathogenetic mechanisms are discussed.
 ...
PMID:Epileptic seizure during aspirin and caffeine withdrawal in a drug induced headache. 907 14

Caffeine consumption may cause headache, particularly migraine. Its withdrawal also produces headaches and may be related to weekend migraine attacks. Transcranial Doppler sonography (TCD) has shown changes in cerebral blood flow velocities (BFV) during and between attacks of migraine. In order to examine whether headache and changes in BFV could develop from controlled caffeine alterations, 20 healthy volunteers without a headache history, underwent clinical evaluation, TCD and serum caffeine measurements on four occasions, comparing conditions of regular caffeine intake, caffeine withdrawal and "re-caffeination". After 24 h of complete caffeine abstinence, 10 suffered from moderate to severe headaches with complete recovery within 1 h after caffeine intake. The BFVs in both middle cerebral, both posterior cerebral and basilar arteries were higher following the withdrawal period, reaching statistical significance in the left middle cerebral basilar and both posterior cerebral arteries. BFVs decreased significantly within half an hour after caffeine intake in all subjects, and were similar to baseline values after 2 h. Our results emphasize the relationship between caffeine withdrawal, the development of headache and alterations in cerebral blood flow velocities. Also, these findings indicate that accurate interpretation of TCD measurements should account for the influence of caffeine on BFVs.
Cephalalgia 1997 May
PMID:Influence of caffeine and caffeine withdrawal on headache and cerebral blood flow velocities. 917 Mar 42

Eight exclusive cola drinkers in Experiment 1 (mean caffeine intake = 157 +/- 74 mg/day) and 16 drinkers of both cola and coffee in Experiment 2 (mean caffeine intake = 579 +/- 201 mg/day) underwent 6 independent, double-blind weekly trials. Each trial began with a randomized cross-over sampling period of 1 day of access to noncaffeinated cola and 1 day of access to caffeinated (33 mg/8 oz) cola. During the subsequent 1- or 2-day test period, participants had unlimited concurrent access to the 2 colas. Reliable caffeine self-administration occurred in 2 of 8 participants in Experiment 1 and in 4 of 16 participants in Experiment 2. Self-reported drowsiness, fatigue, and headache were higher when participants received only placebo colas in Experiment 2, but not Experiment 1. Caffeine self-administration via cola occurs both among people whose primary source of caffeine is cola and among those whose primary source of caffeine is coffee.
 ...
PMID:Caffeine self-administration in humans: 1. Efficacy of cola vehicle. 926 77

The effects of short-term deprivation of caffeinated beverages on mood, withdrawal symptoms, and psychomotor performance were studied in habitual coffee drinkers. Twenty-four male and female coffee drinkers were tested at midday (1130-1330 h) under two conditions. On one day they consumed caffeinated beverages ad lib prior to testing, and on the other they remained caffeine abstinent. The order of treatments was counterbalanced. Mood and withdrawal symptom reports were collected by questionnaires. Psychomotor performance was tested with a computerized test battery. Caffeinated-beverage deprivation was associated with decreased vigor and increased fatigue and with symptoms including headache. No changes in psychomotor performance were observed. Even short periods of caffeinated-beverage deprivation, equivalent in length to missing regular morning coffee, can produce noticeable unpleasant caffeine-withdrawal symptoms by the middle of the day. These symptoms may be a common side effect of habitual caffeinated beverage consumption.
 ...
PMID:Effects of brief caffeinated-beverage deprivation on mood, symptoms, and psychomotor performance. 926 92


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>